NasdaqGS:ONCBiotechs
BeOne Medicines (ONC) Stock After New BRUKINSA And BTK Degrader Data What Is The Valuation Story Now
BeOne Medicines (NasdaqGS:ONC) is back in focus after EHA 2026 data for BRUKINSA, tacabrutideg and the BRUKINSA plus sonrotoclax regimen in B-cell malignancies, highlighting long-term efficacy signals and detailed real-world evidence.
See our latest analysis for BeOne Medicines.
Despite the strong flow of clinical and index news, BeOne Medicines’ shares have eased, with the 30-day share price return down 9.82% and year-to-date share price return down 14.96%, while the 3-year total shareholder...